Tolerance Induction and The Immunobiology of Factor VIII in Hemophilia A
The development of inhibitory antibodies to the factor VIII (FVIII) protein is the greatest complication in the management of hemophilia A patients. These antibodies, which form in approximately 25% of patients, neutralize the procoagulant activity of FVIII. There are limited treatment options to ma...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en en |
| Published: |
2010
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1974/6107 |